Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. - Mendell JR; Muntoni F; McDonald CM; Mercuri EM; Ciafaloni E; Komaki H; Leon-Astudillo C; Nascimento A; Proud C; Schara-Schmidt U; Veerapandiyan A; Zaidman CM; et al. (Neurology and therapy, 2026)